Hepatitis C Virus and Hepatocellular Carcinoma (HCV & HCC): Clinical and Experimental Aspects, and Medical or Surgical Strategies

Dear Colleagues,

This collection is the second edition of the Special Issue “Hepatitis C Virus and Hepatocellular Carcinoma (HCV & HCC)” (https://www.mdpi.com/journal/cancers/special_issues/hcv_hcc).

Chronic hepatitis C is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. The new antiviral era, revolutionized the efficacy and outcome of chronic HCV infection with the use of direct acting drugs (DAAs), by the maximization of viral eradication and the reduction of cases with cirrhosis and related-complications. The open issues and debated areas in Literature on HCV&HCC relations are manifold and this Cancers special issue wants to be focused on the following main topics:

- I section: Evidence of HCV infection and development of liver cancer.

In this section, are encouraged papers that will provide aspects and biological and/or molecular links between the HCV viral infection and the growth and expansion of liver tumors.

- II section: Interplay between DAAs and risk of HCC.

Here, are considered publications that described treated cohorts or meta-analyses, reporting the prevalence and risk factors for ongoing hepatic and extrahepatic complications after DAA therapies, but also the efficacious outcome, particularly by life-expectancy restoration in cases with SVR.

- III section: Liver cirrhosis and risk factors of HCC: medical and surgical strategies.

This section is aimed to focus on patient characteristics and epidemiological and clinical features suggestive of liver cancer development in chronic hepatitis C, in particular also to the description of medical and surgical curative strategies, including aspects of liver transplantation, and of radiological and surgical aspects predictive of HCC occurrence and/ recurrence.

Dr. Liliana Chemello
Dr. Luisa Cavalletto
Prof. Dr. Erica Villa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.